Convince investors of innovations

At HEMEX, startups receive a podium to present their advanced health care innovations to potential investors in detail and in a small group. From the implant system for the treatment of chronic lymphedema swelling to the method for self-measurement of sleep disorders and therapy for patients with multi-resistant cancers to the technology for combating the causes of periodontitis – four promising young companies took part in the first physical pitch event last year since the outbreak of the pandemic Liestal took part and asked critical questions.

HEMEX receives CHF 7.1 million

HEMEX, partner of the Basel Area Business & Innovation, wants to use the fresh capital to finance initial investments in the early phase of start-ups that are active in the life sciences. The Liestal-based company also plans to recruit new team members for clinical activities, quality assurance and regulatory affairs.

EIC Pathfinder beneficiary HEMEX completes a €6.8 million Series C round

HEMEX, an EIC Pathfinder beneficiary company, has completed another fundraising round. After the first closing in February 2021, they secured a Series C round, increasing the amount to approximately €6.8 million (CHF 7.1 million).

HEMEX banks 7.1 million Swiss Francs

Hemex has raised a total of 7.1 million Swiss francs as part of a Series C financing round. The company for clinical contract research and investments in start-ups intends to finance firms in their early phase in addition to supporting plans aimed at hiring new team members.

HEMEX attracts Swiss investors

A group of experienced Swiss entrepreneurs and private investors have participated in a significantly oversubscribed financing round for HEMEX. The biotech incubator will use the funds to accelerate its global expansion.